J Cancer 2019; 10(3):627-633. doi:10.7150/jca.28660
The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection
1. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan
2. Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute
3. Department of Hepatobiliary Pancreatic Oncology, Kanagawa Cancer Center
4. Department of Surgery, Yokohama City University
Masaaki Murakawa and Toru Aoyama equally contributed this article.
Murakawa M, Aoyama T, Miyagi Y, Kobayashi S, Ueno M, Morimoto M, Numata M, Yamamoto N, Tamagawa H, Yukawa N, Rino Y, Masuda M, Morinaga S. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. J Cancer 2019; 10(3):627-633. doi:10.7150/jca.28660. Available from http://www.jcancer.org/v10p0627.htm
Background: The predictive roles of secreted protein acidic and rich in cysteine (SPARC) in pancreatic ductal adenocarcinoma (PDAC) patients after curative resection have not been clarified. We investigated the correlations between the SPARC expression and the postoperative prognosis.
Methods: We retrospectively analyzed the clinical data from consecutive patients who underwent curative resection for pancreatic cancer in our institution from 2005 to 2014. Stromal SPARC expression was analyzed by immunohistochemistry on tumor tissue microarrays (TMAs) from the patients.
Results: A total of 179 patients were enrolled to this study. The median follow-up period of the present study was 62.1 months. Seventy patients had positive SPARC expression (39.1%). There were no significant differences between the positive SPARC-positive group and the SPARC-negative group. In the survival analysis, there was a significant difference between the SPARC-positive and SPARC-negative groups in the 5-year overall survival (OS) rates after surgery, which were 8.1% and 19.8%, respectively (p=0.0316). A univariate analysis showed that the SPARC expression, size of tumor, lymph node metastasis, and residual tumor were possible prognostic factors. A multivariate analysis showed that the SPARC expression (hazard ratio [HR]: 1.44, 95% confidence interval [CI]: 1.017-2.051), lymph node metastasis (HR: 2.019, 95% CI: 1.318-3.091), and residual tumor (HR: 1.648, 95% CI: 1.132-2.401) were independent prognostic factors.
Conclusions: The stromal SPARC expression in resectable pancreatic cancer patients might be useful as a prognostic marker.
Keywords: pancreatic cancer, secreted protein acidic and rich in cysteine, prognostic factor